Head of the Unit:
Assoc. Prof. Ruth Ladenstein, MD, MBA, cPM
Scientific Assistant, RSA*: Claudia Zeiner, MSc
Statisticians: Evgenia Glogova, MSc, junior statistician l Monica Kiesewetter, data management and statistics l Ulrike Pötschger, MSc, senior statistician
Leukaemia and Lymphoma Studies
Corinne Grafl, RSA l Saelde Baumgartner, BSc, RSA l Nora Mühlegger, MSc, RSA l Marek Nykiel, RSA l
Assoc. Prof. Georg Mann, MD, CC** (ALL and Lymphoma Studies) l Assoc. Prof. Andishe Attarbashi, MD, CC (ALL and Lymphoma Studies) l Assoc. Prof. Michael Dworzak, MD, CC (AML, MDS, CML Studies)
Studies in Solid Tumours
Eva Sorz, RSA l Ingrid Pribill, PhD, RSA l Dasa Janousek, MSc, RSA
Assoc. Prof. Ruth Ladenstein, MD, MBA, cPM, CC (Neuroblastoma, Soft Tissue Tumours, Ewing Sarcoma) l Assoc. Prof. Leo Kager, MD, CC (Osteosarcoma, Nephroblastoma)
Stem Cell Transplantation Studies
Ingeborg Hirsch, MSc, RSA l Susanne Karlhuber, PhD, RSA l Barbara Kristufek, RSA l Assoc. Prof. Susanne Matthes-Martin, MD, CC (Allogene Stem Cell Transplantation) l Prof. Christina Peters, MD, CC (Allogene Stem Cell Transplantation) l Assoc. Prof. Ruth Ladenstein, MD, MBA, cPM, CC (Autologous Stem Cell Transplantation)
*RSA: Research and Study Assistant
**CC: Clinical Studies Leader and Collaborator
About the Clinical Trials Unit S²IRP
Collecting and evaluating patient data is of utmost importance for clinical trials.
In total, the S2IRP has registered data from more than 9,000 patients. International studies focus on the fields of Langerhans’ cell histiocytosis (study centre of LCH trials I, II, III), neuroblastoma (study centre of the European High Risk Neuroblastoma Study HR-NBL-1/SIOPEN) and the stem cell transplantation of acute lymphoblastic leukaemia (study centre of the international ALL-SCT Study).
Activities of the S2IRP/Coordinating Centre for paediatric-oncological trials.
The Clinical Trial Unit has been developed and trained towards the necessary expertise and manages the full scope of tasks as required according to GCP and European Directives as well as national legal requirements (AMG [Arzneimittelgesetz] - Austrian Pharmaceuticals Act). For more details, please visit the S2IRP section.
The European Network for Cancer Research in Children and Adolescents (ENCCA)
The Network of Excellence ENCCA is funded by the European Union’s 7th Framework Programme under the Health topic “Structuring clinical research in paediatric and adolescent oncology in Europe”.
Headed by Dr. Ruth Ladenstein, S2IRP plays a key role in the coordination of this consortium that comprises influent European research institutes and organisations recognised for their excellence in paediatric oncology that are dedicated to improve the treatment of children and adolescents suffering from cancer. Ultimately ENCCA aims at facilitating access to therapies and standards of care across Europe to reduce the existing gaps and limitations in paediatric oncology.
O.K.ids A Project on the Political Agenda
An Austrian Network Application to the Austrian Ministry of Health There is a political agenda to raise awareness for the clinical research components for all the respective Paediatric Oncology tasks and research areas in public and there are ongoing efforts to enhance visibility and recognition of these fields in Austria also vis-à-vis universities and Ministries of Health & Science. Close collaborations with the Competent Authorities (AGES) and the Ministry of Health are ongoing.
The primary aim of the O.K.ids project application in 2008 was to fund basic Clinical Trial Unit structures in 5 centres in Austria to cope with requirements of competent authorities and to foster drug development and approval of medicines for children and adolescents. S2IRP was proposed as major Network Coordination Unit. These efforts were driven by the vision to support solutions to overcome off-label and off-licence use in clinical trials for children and adolescents and hence to reduce administrative burden in the future.
A project handbook was written on request of the Austrian Ministry of Health. However, so far the paediatric network has not achieved government support and funding. Political negotiations and working groups ongoing (AGES - Kindergesundheitsdialog). In addition, the commitment in “Politische Kindermedizin” in Austria and problems were summarised in a book chapter for reference in more details.
EHN (EuroHistioNet) Consortium
EuroHistioNet was funded by the Public European Health Agency (PEHA) under the 6th EU Framework Programme (FP6) and coordinated by the Public Assistance - Hospitals of Paris. This reference network for Langerhans Cell Histiocytosis and associated syndromes has been brought up to join efforts in increasing the knowledge of the disease, improving quantity and quality of knowledge exchange, producing guidelines and setting up an international data base. Any newly acquired information will be distributed by a web portal for LCH professionals, doctors and patients at www.eurohistio.net